-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205

Benzinga·08/07/2026 17:04:56
Listen to the news
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.